Risk stratification for ventricular arrhythmias and sudden cardiac death in arrhythmogenic right ventricular cardiomyopathy: an update

Julia Cadrin-Tourigny, Laurens P. Bosman, Rafik Tadros, Mario Talajic, Lena Rivard, Cynthia Anne James, Paul Khairy

Research output: Contribution to journalReview article

Abstract

Introduction: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetically determined disease associated with a significant risk of ventricular arrhythmias and sudden cardiac death (SCD). Implantable cardioverter-defibrillators (ICDs) are the only effective preventive measure. Over the past 30 years, much effort has been invested in determining predictors of adverse arrhythmic events in these patients. Areas covered: This review summarizes available evidence on risk stratification for ARVC, with an emphasis on recent research findings. While efforts are ongoing to define risk predictors, several recent publications have synthetized and built on this knowledge base. A recently published meta-analysis has clarified the strongest predictors of ventricular arrhythmias in ARVC, which vary depending on the population included. Three management guidelines/expert consensus documents have integrated the previously described risk predictors into proposed ICD recommendations. Furthermore, a risk prediction model has allowed the integration of multiple risk factors to provide individualized risk prediction and to inform shared-decision making regarding ICD implantation. Expert opinion: Over the past few years, knowledge of risk prediction in ARVC has been consolidated and refined. Further improvements may be made by the considering additional predictors such as exercise and by targeting more specific surrogate outcomes for SCD.

Original languageEnglish (US)
JournalExpert Review of Cardiovascular Therapy
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Arrhythmogenic Right Ventricular Dysplasia
Sudden Cardiac Death
Cardiac Arrhythmias
Implantable Defibrillators
Knowledge Bases
Expert Testimony
Meta-Analysis
Consensus
Decision Making
Guidelines
Exercise
Research

Keywords

  • Arrhythmogenic right ventricular cardiomyopathy
  • implantable cardioverter defibrillator
  • inherited heart disease
  • sudden cardiac death
  • ventricular tachycardia

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Risk stratification for ventricular arrhythmias and sudden cardiac death in arrhythmogenic right ventricular cardiomyopathy : an update. / Cadrin-Tourigny, Julia; Bosman, Laurens P.; Tadros, Rafik; Talajic, Mario; Rivard, Lena; James, Cynthia Anne; Khairy, Paul.

In: Expert Review of Cardiovascular Therapy, 01.01.2019.

Research output: Contribution to journalReview article

@article{0fc0e309b71d45feb4145bfaaa91d815,
title = "Risk stratification for ventricular arrhythmias and sudden cardiac death in arrhythmogenic right ventricular cardiomyopathy: an update",
abstract = "Introduction: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetically determined disease associated with a significant risk of ventricular arrhythmias and sudden cardiac death (SCD). Implantable cardioverter-defibrillators (ICDs) are the only effective preventive measure. Over the past 30 years, much effort has been invested in determining predictors of adverse arrhythmic events in these patients. Areas covered: This review summarizes available evidence on risk stratification for ARVC, with an emphasis on recent research findings. While efforts are ongoing to define risk predictors, several recent publications have synthetized and built on this knowledge base. A recently published meta-analysis has clarified the strongest predictors of ventricular arrhythmias in ARVC, which vary depending on the population included. Three management guidelines/expert consensus documents have integrated the previously described risk predictors into proposed ICD recommendations. Furthermore, a risk prediction model has allowed the integration of multiple risk factors to provide individualized risk prediction and to inform shared-decision making regarding ICD implantation. Expert opinion: Over the past few years, knowledge of risk prediction in ARVC has been consolidated and refined. Further improvements may be made by the considering additional predictors such as exercise and by targeting more specific surrogate outcomes for SCD.",
keywords = "Arrhythmogenic right ventricular cardiomyopathy, implantable cardioverter defibrillator, inherited heart disease, sudden cardiac death, ventricular tachycardia",
author = "Julia Cadrin-Tourigny and Bosman, {Laurens P.} and Rafik Tadros and Mario Talajic and Lena Rivard and James, {Cynthia Anne} and Paul Khairy",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/14779072.2019.1657831",
language = "English (US)",
journal = "Expert Review of Cardiovascular Therapy",
issn = "1477-9072",
publisher = "Expert Reviews Ltd.",

}

TY - JOUR

T1 - Risk stratification for ventricular arrhythmias and sudden cardiac death in arrhythmogenic right ventricular cardiomyopathy

T2 - an update

AU - Cadrin-Tourigny, Julia

AU - Bosman, Laurens P.

AU - Tadros, Rafik

AU - Talajic, Mario

AU - Rivard, Lena

AU - James, Cynthia Anne

AU - Khairy, Paul

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetically determined disease associated with a significant risk of ventricular arrhythmias and sudden cardiac death (SCD). Implantable cardioverter-defibrillators (ICDs) are the only effective preventive measure. Over the past 30 years, much effort has been invested in determining predictors of adverse arrhythmic events in these patients. Areas covered: This review summarizes available evidence on risk stratification for ARVC, with an emphasis on recent research findings. While efforts are ongoing to define risk predictors, several recent publications have synthetized and built on this knowledge base. A recently published meta-analysis has clarified the strongest predictors of ventricular arrhythmias in ARVC, which vary depending on the population included. Three management guidelines/expert consensus documents have integrated the previously described risk predictors into proposed ICD recommendations. Furthermore, a risk prediction model has allowed the integration of multiple risk factors to provide individualized risk prediction and to inform shared-decision making regarding ICD implantation. Expert opinion: Over the past few years, knowledge of risk prediction in ARVC has been consolidated and refined. Further improvements may be made by the considering additional predictors such as exercise and by targeting more specific surrogate outcomes for SCD.

AB - Introduction: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetically determined disease associated with a significant risk of ventricular arrhythmias and sudden cardiac death (SCD). Implantable cardioverter-defibrillators (ICDs) are the only effective preventive measure. Over the past 30 years, much effort has been invested in determining predictors of adverse arrhythmic events in these patients. Areas covered: This review summarizes available evidence on risk stratification for ARVC, with an emphasis on recent research findings. While efforts are ongoing to define risk predictors, several recent publications have synthetized and built on this knowledge base. A recently published meta-analysis has clarified the strongest predictors of ventricular arrhythmias in ARVC, which vary depending on the population included. Three management guidelines/expert consensus documents have integrated the previously described risk predictors into proposed ICD recommendations. Furthermore, a risk prediction model has allowed the integration of multiple risk factors to provide individualized risk prediction and to inform shared-decision making regarding ICD implantation. Expert opinion: Over the past few years, knowledge of risk prediction in ARVC has been consolidated and refined. Further improvements may be made by the considering additional predictors such as exercise and by targeting more specific surrogate outcomes for SCD.

KW - Arrhythmogenic right ventricular cardiomyopathy

KW - implantable cardioverter defibrillator

KW - inherited heart disease

KW - sudden cardiac death

KW - ventricular tachycardia

UR - http://www.scopus.com/inward/record.url?scp=85070988726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070988726&partnerID=8YFLogxK

U2 - 10.1080/14779072.2019.1657831

DO - 10.1080/14779072.2019.1657831

M3 - Review article

C2 - 31422711

AN - SCOPUS:85070988726

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

SN - 1477-9072

ER -